Psychotic Disorders & High Psychosis Risk: psilocybin research evidence

Why this category is marked negative

Psilocybin can profoundly alter perception, belief stability, and self-boundaries. For people with schizophrenia-spectrum illness, bipolar disorder with psychotic features, or elevated psychosis vulnerability, those effects are more likely to destabilise than to heal.

What the evidence emphasises

• Modern trial protocols typically exclude psychotic disorders and often first-degree relatives with such histories.
• Meta-analytic incidence of psychedelic-induced psychosis is low in general-population samples but materially higher in older uncontrolled cohorts that included schizophrenia; a minority of induced-psychosis cases later develop schizophrenia.
• Systematic case-report reviews document schizophrenia-spectrum and major affective presentations after psychedelic exposure; recovery is less consistent for schizophrenia-spectrum outcomes.
• Contemporary case reports describe psychosis with catatonic features after heavy repeated psilocybin use in predisposed patients (for example depression plus cannabis use and personality-vulnerability traits).

How to read "negative" on PSILORIS

Negative means the balance of evidence and risk currently argues against therapeutic use for this indication, not that every related research question is forever closed. Any future exception would require specialised protocols far beyond general educational guidance.